CRISPR Therapeutics' second quarter revenue and EPS beat expectations, driven by strong CASGEVY sales growth.

CRISPR Therapeutics reported second quarter 2026 total revenue of $10.2 million and a net loss of $0.94 per share, beating analyst estimates for both metrics. The results were driven by the accelerating commercial launch of its gene therapy, CASGEVY.

Key Highlights

• CASGEVY product sales grew to $76 million, a 151% increase year-over-year and 78% quarter-over-quarter.
• The FDA expanded CASGEVY's approval to include children as young as 2 years old, potentially adding 5,500 eligible patients.
• The company ended the quarter with a strong cash position of $2.36 billion.